TERT启动子突变在甲状腺癌中的研究进展

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (3): 350-354.

TERT启动子突变在甲状腺癌中的研究进展

唐新月^1,2，石峰³，黎翠林^1,2，刘剑秋^1,2，李智^1,2

¹ 中南大学湘雅医院临床药理研究所，长沙 410008，湖南； ²中南大学临床药理研究所，遗传药理学湖南省重点实验室，长沙 410078，湖南；³ 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院，长沙 410006，湖南

收稿日期:2016-11-09 修回日期:2016-12-22 出版日期:2017-03-26 发布日期:2017-03-29
通讯作者: 李智，男，博士，副教授、硕士生导师，研究方向：药物基因组学与个体化医学。 Tel: 0731-84805380 E-mail: lizhi489@163.com
作者简介:唐新月，女，硕士研究生，研究方向：药物基因组学与个体化医学。 Tel: 0731-84805380 E-mail: xinyue89111@163.com
基金资助:
国家新药创制重大专项(2012ZX09303013-004)；湖南省高校创新平台开放基金项目(13K002)

Research progress of TERT promoter mutation in thyroid cancer

TANG Xinyue^1,2, SHI Feng³, LI Cuilin ^1,2, LIU Jianqiu ^1,2, LI Zhi ^1,2

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008，Hunan, China; ²Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, China;³ Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410006, Hunan, China

Received:2016-11-09 Revised:2016-12-22 Online:2017-03-26 Published:2017-03-29

摘要/Abstract

摘要：

甲状腺癌是内分泌系统常见的肿瘤之一，其发病率逐年上升。端粒酶逆转录酶（telomerase reverse transcriptase,TERT）启动子突变(C228T,C250T)自2013年在甲状腺癌中被发现以来，其与甲状腺癌的关系即被广泛研究。绝大多数研究认为该突变与甲状腺癌的发生及临床病理特征以及不良预后息息相关，该突变为甲状腺癌致病基因突变。本文对TERT启动子突变在不同类型甲状腺癌中的发生及其临床意义进行综述，以期为TERT启动子突变在甲状腺癌中的研究及甲状腺癌的分子诊治提供新思路。

关键词: 甲状腺癌, 端粒酶逆转录酶, 启动子突变

Abstract:

Thyroid cancer is a common endocrine malignancy and its morbidity raised rapidly in recent years. The association between TERT promoter mutations (C228T,C250T) and clinical outcomes have been investigated since they were confirmed in thyroid cancer (including differentiated thyroid cancer and anaplastic thyroid cancer) in 2013. Most studies suggest the mutations are associated with thyroid cancer, the clinical outcomes and poor prognosis. The two mutations are considered to be oncogenic mutations. In order to provide a new sight into the research of TERT promoter mutation, diagnosis and treatment of thyroid cancer, we summarized the incidence of TERT promoter mutation in different types of thyroid cancer and the clinical relevance of these mutations.

Key words: thyroid cancer, telomerase reverse transcriptase, promoter mutation

中图分类号:

R736.1

唐新月，石峰，黎翠林，刘剑秋，李智. TERT启动子突变在甲状腺癌中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(3): 350-354.

TANG Xinyue, SHI Feng, LI Cuilin, LIU Jianqiu, LI Zhi. Research progress of TERT promoter mutation in thyroid cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 350-354.

参考文献

［1］Fallet E, Jolivet P, Soudet J, et al. Length-dependent processing of telomeres in the absence of telomerase［J］. Nucleic Acids Res, 2014, 42(6): 3648-3665.
［2］Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer［J］. Science, 1994, 266(5193): 2011-2015.
［3］李小宁，杨正海，李静，等. 不同基因型丙型肝炎病毒非结构蛋白NS3对端粒酶活性的研究［J］. 中国临床药理学与治疗学, 2015, 20(2): 534-538.
［4］Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma［J］. Science, 2013, 339(6122): 959-961.
［5］Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter［J］. Hum Mol Genet, 1999, 8(1): 137-142.
［6］Ramlee MK, Wang J, Toh WX, et al. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene［J］. Genes (Basel), 2016, 7(8): pii: E50.
［7］Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers［J］. Nat Commun, 2013, 4: 2185.
［8］Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［9］Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 ［see commetns］［J］. Cancer-Am Cancer Soc, 1998, 83(12): 2638-2648.
［10］Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers［J］. Endocr Relat Cancer, 2013, 20(4): 603-610.
［11］Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease［J］. J Clin Endocrinol Metab, 2013, 98(9): E1562-1566.
［12］Melo M, Da RA, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas［J］. J Clin Endocrinol Metab, 2014, 99(5): E754-765.
［13］Qasem E, Murugan AK, Al-Hindi H, et al. TERT promoter mutations in thyroid cancer: A report from a Middle Eastern population［J］. Endocr Relat Cancer, 2015, 22(6): 901-908.
［14］Liu R, Xing M. TERT promoter mutations in thyroid cancer［J］. Endocr-Relat Cancer, 2016,23(3): R143-155.
［15］Wang N, Liu T, Sofiadis A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA［J］. Cancer-Am Cancer Soc, 2014, 120(19): 2965-2979.
［16］Alzahrani AS, Alsaadi R, Murugan AK, et al. TERT promoter mutations in thyroid cancer［J］. Hormones and Cancer, 2016, 7(3): 165-177.
［17］de Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas［J］. Thyroid, 2015, 25(9): 1013-1019.
［18］Ballester LY, Sarabia SF, Sayeed H, et al. Integrating molecular testing in the diagnosis and management of children with thyroid lesions［J］. Pediatr Dev Pathol, 2016, 19(2): 94-100.
［19］Muzza M, Colombo C, Rossi S, et al. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization［J］. Mol Cell Endocrinol, 2015, 399: 288-295.
［20］Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence［J］. J Clin Oncol, 2014, 32(25): 2718-2726.
［21］Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer［J］. J Clin Endocrinol Metab, 2014, 99(6): E1130-1136.
［22］Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas［J］. Oncogene, 2014, 33(42): 4978-4984.
［23］Shi X, Liu R, Qu S, et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer［J］. J Clin Endocrinol Metab, 2015, 100(4): E632-637.
［24］Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer［J］. Endocr Relat Cancer, 2016, 23(10):813-823.
［25］Gandolfi G, Ragazzi M, Frasoldati A, et al. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma［J］. Eur J Endocrinol, 2015, 172(4): 403-413.
［26］Jin L, Chen E, Dong S, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: A study of 653 patients［J］. Oncotarget, 2016, 7(14): 18346-18355.
［27］Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) Mutation-Prevalent population［J］. Thyroid, 2016, 26(7): 901-910.
［28］Li Y, Cheng HS, Chng WJ, et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas［J］. Proc Natl Acad Sci U S A, 2016, 113(50): 14402-14407.

[1]	陈文捷, 王亚兵, 陈晓琳, 任俊玲, 赵晚君, 陈斌. 碘难治性分化型甲状腺癌的最新研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 116-120.
[2]	苏姗，张迪，王强梅，甄东户. 维生素D与甲状腺疾病的相关性[J]. 中国临床药理学与治疗学, 2020, 25(1): 94-100.
[3]	黄浩, 李秀, 肖宏, 傅雷, 余兰才, 林世和, 易艳东. 靶向siRNA下调人结直肠癌 Colo320 细胞端粒长度与端粒酶逆转录酶基因表达的研究[J]. 中国临床药理学与治疗学, 2008, 13(10): 1134-1138.